Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
10 stopped studies mapped to Transformed Non-Hodgkin Lymphoma and descendants · 100% state a reason
Over the 10 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy… | Phase 2 | terminated | Dec 20, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials